EUVIMEDEUVIMED entdecken
Crossref

Roflumilast mitigates idiopathic pulmonary fibrosis via inhibition of iron accumulation and ferroptosis

Liting Feng, Shuangyu Han, Yajing Li, Siyu Zhan, Li Li, Yubao Wang, Jing Feng

European Journal of Pharmacology · 2025-12 · 1008 · 178385

DOI: 10.1016/j.ejphar.2025.178385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2025-12. Verfasst von Liting Feng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, 300350, China; Haihe Clinical School, Tia…. Hauptthemen laut MEDLINE: Ferroptosis, Benzamides, Aminopyridines, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Major Science and Technology Projects of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To investigate roflumilast's anti-fibrotic effects in idiopathic pulmonary fibrosis (IPF) and its role in suppressing ferroptosis. METHODS: This study utilized bleomycin (BLM) -induced murine IPF and transforming growth factor beta 1 (TGF-β1) -stimulated in vitro models to assess the anti-fibrotic effects of roflumilast. The assessment was conducted by monitoring body weight, examining lung histopathology, and employing immunohistochemistry to detect fibrotic markers. The study also evaluated roflumilast's impact on iron accumulation and ferroptosis by measuring malondialdehyde (MDA), iron content, reactive oxygen species (ROS), and lipid ROS in murine lung fibroblasts and alveolar epithelial cells. Mechanistically, the regulation of solute carrier family 40 member 1 (Slc40a1), transferrin receptor 1 (Tfrc), ferritin heavy chain 1 (Fth1), glutathione peroxidase 4 (GPX4), and ferroptosis suppressor protein 1 (FSP1) by roflumilast was confirmed through cAMP response element-binding protein (CREB) inhibition/knockdown experiments. RESULTS: Roflumilast effectively mitigated BLM-induced weight loss, lung fibrosis, and collagen deposition, thereby reducing levels of hydroxyproline and fibrotic markers. In vitro studies demonstrated its ability to suppress fibroblast activation and epithelial-mesenchymal transition (EMT). Additionally, Roflumilast inhibited ferroptosis through CREB-mediated regulation of Slc40a1, Tfrc, and Fth1, as well as upregulation of GPX4 and FSP1, leading to a decrease in lipid peroxidation. CONCLUSIONS: Roflumilast activates CREB, thereby restoring iron homeostasis (by upregulating Slc40a1 and Fth1, while downregulating Tfrc. Additionally, it suppresses ferroptosis through the enhancement of GPX4 and FSP1, thereby ameliorating the progression of IPF. This dual targeting of iron homeostasis and lipid peroxidation underscores its therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisBenzamidesAminopyridinesIdiopathic Pulmonary FibrosisIronAnimalsMiceBleomycinMaleFibroblastsCyclopropanesLungReactive Oxygen SpeciesMice, Inbred C57BLHumansDisease Models, AnimalCyclic AMP Response Element-Binding Protein

Stichwörter der Autor:innen

FerroptosisFerroptosis suppressor protein 1 (FSP1)Glutathione peroxidase 4 (GPX4)Idiopathic pulmonary fibrosis (IPF)RoflumilastcAMP response element-binding protein (CREB)

Substanzen

BenzamidesAminopyridinesRoflumilastIronBleomycinCyclopropanesReactive Oxygen SpeciesCyclic AMP Response Element-Binding Protein

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, 300350, China; Haihe Clinical School, Tianjin Medical University, Tianjin, 300222, China.
  • Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, 300350, China.
  • Haihe Clinical School, Tianjin Medical University, Tianjin, 300222, China.
  • Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, 300350, China. Electronic address: wangyubao@tmu.edu.cn.
  • Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, 300350, China. Electronic address: tmugh_fj@tmu.edu.cn.

Förderung

  • National Major Science and Technology Projects of China
  • National Natural Science Foundation of China

Zitieren

APA

Feng, L., Han, S., Li, Y., Zhan, S., Li, L., Wang, Y., & Feng, J. (2025). Roflumilast mitigates idiopathic pulmonary fibrosis via inhibition of iron accumulation and ferroptosis. European Journal of Pharmacology, 1008, 178385. https://doi.org/10.1016/j.ejphar.2025.178385

Vancouver

Feng L, Han S, Li Y, Zhan S, Li L, Wang Y, et al. Roflumilast mitigates idiopathic pulmonary fibrosis via inhibition of iron accumulation and ferroptosis. European Journal of Pharmacology. 2025;1008:178385. doi:10.1016/j.ejphar.2025.178385

BibTeX
@article{Feng2025,
  author = {Feng, Liting and Han, Shuangyu and Li, Yajing and Zhan, Siyu and Li, Li and Wang, Yubao and Feng, Jing},
  title = {Roflumilast mitigates idiopathic pulmonary fibrosis via inhibition of iron accumulation and ferroptosis},
  journal = {European Journal of Pharmacology},
  year = {2025},
  volume = {1008},
  pages = {178385},
  doi = {10.1016/j.ejphar.2025.178385}
}
Kostenlos starten →